

The All.Can initiative –



Changing cancer care together

Patients' perspectives on improving efficiency in cancer care

Kathy Oliver¹; Matti Aapro²; Tit Albreht³; Shannon Boldon⁴; Szymon Chrostowski⁵; Francesco Florindi⁶; Benjamin Gandouet⁷; Pascal Garel⁸; Rainer Hess⁹; Sabrina Hanna¹⁰; Rishi Hazarika¹¹; Denis Lacombe¹²; Francesco de Lorenzo¹³; Vivek Muthu¹⁴; Alexander Roediger¹⁴; Titta Rosvall-Puplett¹⁵; Bettina Ryll¹⁶; Gilliosa Spurrier¹⁷; Karin Steinmann¹⁸; Thomas Szucs¹⁹; Suzanne Wait²⁰; Lieve Wierinck²⁰; Wendy Yared²¹

All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (lead sponsor), Amgen and MSD (co-sponsors).

Background

- We face limited resources and a demand for cancer care that will only increase in quantity and complexity in years to come.
- We need to find new ways to make the most of the resources we have.
- This is true in brain tumours as in other areas of cancer.
- Improving the efficiency of cancer care must start with a clear understanding of what outcomes we are trying to achieve for patients.

Waste must be challenged:

Waste is not just money, but time, quality of life, and missed opportunities for patients and their families.



Challenges

- Clear definitions of waste and inefficiency from the patient perspective are currently lacking.
- There are opportunities to improve efficiency across the entire care pathway.



Screening



Diagnosis



Treatment



Follow-up

Are we placing patients at the heart of all decisions?

Are we providing seamless, well-coordinated multidisciplinary care?

Do we measure and understand the impact of given interventions on costs and outcomes?

Are there system-wide accountability mechanisms for outcomes?

About All.Can

- All.Can is a multi-sectoral initiative, which was established to create political and public engagement on the need to improve the efficiency of cancer care – focusing on what matters most to patients.
- All.Can includes patient organisations, policymakers, healthcare professionals, research and industry representatives from across Europe and Canada.

We aim to create a highly credible, multi-sectoral platform to drive better efficiency across the cancer care pathway:



Ensure patient-relevant outcomes



Invest in data



Instil concrete mechanisms to create accountability



Create political will

Our activities:

All.Can is conducting a comprehensive qualitative study and survey to gather perspectives from patients and caregivers on what waste and inefficiency in cancer care look like.

These data will help identify the greatest opportunities to improve efficiency in cancer care, and focus policy efforts to make meaningful changes for patients and families.

Patient survey

on waste and inefficiency in cancer care



Healthcare professional survey
to 'mirror' patient survey

These data will give:

- patient-driven definitions of waste and inefficiency
- clarity on where greatest efforts are needed to make meaningful changes to patient outcomes

Policy engagement (national and EU)

- Focused policy actions, implemented via roadmap
- Engagement tools for all stakeholders

Conclusions

- The findings from the patient survey will ultimately be used by All.Can to develop patient advocacy, and public and policy engagement tools.
- They will also help develop focused policy proposals to improve the efficiency of cancer care.

¹ The International Brain Tumour Alliance, UK; ² Clinique de Genolier, Switzerland; ³ National Institute of Public Health, Slovenia; ⁴ The Health Policy Partnership, UK; ⁵ Polish Cancer Patient Coalition, Poland; ⁶ European Cancer Patients Coalition, Belgium; ⁷ Oncopole-Sciences du Vivant et Santé Publique, France; ⁸ European Hospital and Healthcare Federation, Belgium; ⁹ GVG-Committee on Health Goals, Germany; ¹⁰ Save Your Skin Foundation, Canada; ¹¹ The International Consortium for Health Outcomes Measurement, UK; ¹² European Organization for Research and Treatment of Cancer, Belgium; ¹³ Marivek Health Consulting, UK; ¹⁴ MSD, Switzerland; ¹⁵ Bristol Myers Squibb, Belgium; ¹⁶ Melanoma Patient Network Europe; ¹⁷ Melanoma Patient Network Europe & Mèlanome France, France; ¹⁸ Amgen, Switzerland; ¹⁹ University of Basel, Switzerland; ²⁰ European Parliament, Belgium; ²¹ Association of European Cancer Leagues, Belgium.